Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 5 August 2022, including: planned US drug pricing legislation in focus; solid quarter but no Seagen Inc. announcement for Merck & Co., Inc.; AbbVie Inc.’s Gonzalez sounds alarm over US pricing legislation; Alnylam Pharmaceuticals Inc. ready to expand in amyloidosis; and Boehringer Ingelheim GmbH on global Jardiance strategy.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pharma Braces For Potential Landmark Moment For US Drug Price Controls" - Scrip, 2 Aug, 2022.)
(Also see "Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers" - Scrip, 28 Jul, 2022.)
(Also see "AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal" - Scrip, 29 Jul, 2022.)
(Also see "Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results" - Scrip, 3 Aug, 2022.)
(Also see "Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye" - Scrip, 2 Aug, 2022.)